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Abstract
Background  Paradoxical reaction after the initiation of tuberculosis treatment is defined as increased inflammation following 
effective antimycobacterial treatment. This is a phenomenon that can severely complicate a patient’s recovery, potentially 
leading to further morbidity and residual deficits. Paradoxical reaction remains poorly understood regarding its pathophysi-
ology and management. Only a limited number of reports look critically at the available therapeutic options, with evidence 
of the efficacy of prednisolone therapy being primarily limited to extrapulmonary PR only.
Case We describe two HIV negative patients who were admitted to our department with pulmonary tuberculosis, presenting 
with inflammatory patterns attributable to PR and their response to adjunctive steroid therapy.
Discussion and Conclusions The presented cases further highlight the need for immunological studies and randomized trials 
for corticosteroid therapy are needed to better understand this phenomenon as well as provide an evidence-base for anti-
inflammatory treatment. Furthermore, by means of this case series, we are also able to highlight the potential variability in 
the symptomatology of the lesser known PR phenomenon, in which we observed a hypotensive shock-like syndrome not 
previously described in literature.
Keywords Tuberculosis · Paradoxical reaction · Corticosteroids · SIRS
Introduction
Mycobacterium tuberculosis (Mtb) continues to be a daunt-
ing threat despite highly effective and standardized anti-
microbial treatment [1]. Although harmless in its dormant 
form, Mtb is pleiotropic, and with active replication, tuber-
culosis (TB) can be lethal [2]. Indeed, worldwide it is cur-
rently recognized as the number one cause of death due to 
infectious disease with 1.5 million people dying out of the 
estimated 10 million with active disease in 2018 alone [3, 4]. 
This stems largely from the virulence of this pathogen, but 
also the host response may be detrimental in the form of a 
paradoxical reaction (PR). This phenomenon constitutes the 
occurrence of clinical and/or radiographic worsening despite 
effective reduction of bacterial load [5–7]. This diagnosis 
should be considered from 2 weeks after anti-microbial 
therapy initiation, but becomes more likely after 2 months 
[6]. It is a diagnosis of exclusion—failure of therapy, super 
infection and drug-mediated toxicity must first be considered 
[6]. We describe two HIV-negative patients that were treated 
for pulmonary TB who later presented with PR. We report 
their response to adjuvant corticosteroid therapy via clinical 
observation and radiographic imaging.
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Patient A is a 34-year-old male of Moroccan origin who 
was homeless and known with substance abuse. He had no 
recorded previous medical history. He presented with the 
following symptoms: a cough for 7 weeks before admission 
(without hemoptysis), loss of 18.2 kg body weight within a 
3-month period and night sweats matched with severe deple-
tion of muscle mass and fat reserves. On physical examina-
tion, fine crackles were present over the lungs. There were 
no symptoms to suggest extrapulmonary involvement. Body 
temperature was 38.1 ℃. The heart rate upon admission was 
110 bpm with a blood pressure 105/75 mmHg. His BMI 
was 17.2 kg/m2. Upon admission, chest X-rays (see Fig. 1 
below) showed infiltrates in both lungs. He was anemic (Hb 
6.2 mmol/L) with MCV 75.4 fL; C-reactive protein (CRP) 
was elevated 73 mg/L; leukocyte count 11 ×  109/L and 
14.1 ×  109/L the day after admission. This patient was not 
known to be diabetic and blood glucose values matched this 
conclusion. Fluorescent staining of sputum smear micros-
copy showed abundant acid-fast bacilli, and sputum culture 
later revealed M. tuberculosis. Polymerase chain reaction 
(PCR) targeting IS 6110 was positive, consistent with Mtb. 
He tested negative for HIV as well as hepatitis B and C 
co-infections. Bronchoscopic mediastinal lymph node and 
lung tissue cytology specimens displayed the presence of 
polynuclear giant cells in the mediastinal lymph nodes as 
well as the lungs, suggestive of granulomatous necrotizing 
inflammation.
The patient was started on isoniazid, rifampicin, etham-
butol, and pyrazinamide (HRZE). 10 days later, Isoniazid 
was replaced by moxifloxacin after the results of drug sus-
ceptibility testing (DST) revealed isoniazid mono-resistance. 
A month after the initiation of therapy, he developed pyrexia 
and night sweats associated with a failure to gain weight 
after initial clinical improvement. Culture negativity was 
achieved after 2 months of therapy after a progressive reduc-
tion in the bacterial load present in the sputum. Blood and 
urine cultures were negative. The symptoms and signs of 
increased inflammation including deterioration of the chest 
radiograph were highly suggestive of paradoxical inflamma-
tion. He was started on a daily dose of 30 mg of prednisolone 
while TB treatment was continued. His clinical response was 
favorable; his temperature settled, his dyspnea resolved, and 
after 2 weeks, steroids could be tapered, first to 20 mg/day 
when his symptoms started to subside, and subsequently 
the dosage was further reduced and stopped after a total of 
37 days. His clinical course was ultimately uneventful.
Case B
Patient B is a 48-year old man originating from Poland with 
a previous history of chronic alcohol abuse. He presented in 
another health facility with a stabbing chest pain, dyspnea, 
chronic cough (with the presence of hemoptysis) and fever. 
In the month prior, he had observed a weight loss of 10 kg 
with significant muscle wastage impacting his ability to walk 
unaided. Upon auscultation, vesicular breath sounds were 
heard, without crepitations. His temperature was 40.1 ℃, 
blood pressure 117/78 mmHg, heart rate 93 bpm and respira-
tory rate 24 cycles/min. He was anemic with Hb 6.5 mmol/L, 
a leukocyte count of 6.5 ×  109/L and an elevated CRP of 
195 mg/L. His blood glucose was 5.1 mmol/L at presenta-
tion and remained in the normal range during admission. 
Ziehl–Neelsen stained sputum microscopy showed abundant 
Fig. 1  a–c Cavitary changes RUL and bronchogenic spread to RML 
and LUL; b 1 month later, a transient increase in infiltrative changes 
are evident in the LUL and RML that have subsided at month 3 (c) 
and month 4 (not shown). RUL right upper lobe, LUL Left upper 
lobe, RML right medial lobe
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acid-fast bacilli. He was started on HRZE combination ther-
apy; sputum cultures later showed fully susceptible Mtb. 
Vitamin supplementation included pyridoxine and thiamine, 
targeting the patient’s alcohol-related nutritional deficien-
cies. When transferred to our facility, further radiographic 
imaging displayed extensive pulmonary infiltrates bilater-
ally. Initially, he vomited and had diarrhea and we suspected 
central nervous system—or perhaps intestinal or peritoneal 
involvement of tuberculosis. A brain MRI displayed no 
abnormalities allowing for the exclusion of brain involve-
ment. A week later, he deteriorated further with a change in 
his vital parameters, including hypotension (80/50 mmHg), 
and tachycardia (145 bpm). Nevertheless, a gradual reduc-
tion in his dyspnoea and CRP was observed during the first 
weeks despite the hypotension and tachycardia persisting. 
However, a reversal of these clinical improvements was 
seen in the same time frame that followed. We suspected an 
intercurrent nosocomial infection with sepsis, and blood, 
sputum and urine cultures were taken but remained negative. 
Concurrent sputum mycobacterial cultures showed a gradual 
reduction in the mycobacterial load. Furthermore, with each 
sputum culture, an increased time to positivity was observed 
until finally becoming culture negative after 58 days of the 
anti-TB therapy. An ECG showed sinus tachycardia with-
out any other abnormality. Cardiac ultrasound did not show 
pericardial effusion or other abnormalities. Exercise testing 
showed poor exercise tolerance (50 W), but no desaturation 
was noted. The chest X-ray (see Fig. 2) had worsened and 
with CRP increased to 276 mg/L and leukocyte count of 
10.4 ×  109/L, a severe PR was suspected, and he was now 
started on 30 mg prednisolone per day. The response to ster-
oids was positive, but more attenuated and subtle compared 
to patient A. The added corticosteroid could eventually be 
tapered over a 3 month period (Fig. 3), in which he showed 
gradual improvement, with a mild tachycardia (approxi-
mately 100 bpm) persisting for a month following predni-
solone’s cessation before stabilizing. His sputum cultures 
remained negative and his body weight increased, while 
CRP gradually declined to below 20 mg/L. Upon continued 
improvement, displayed by subsequent imaging studies and 
his clinical condition, the patient was discharged from the 
department. However, given our patient’s unsatisfactory rate 
of progress throughout his admission, an extended 9 month 
anti-tuberculosis therapy regimen was implemented, the 
remainder of which was continued on an outpatient basis 
using DOT. 
Discussion
In both patients, we diagnosed PR with a worsening of the 
clinical condition and radiographic pathology. Corticos-
teroids worked well for patient A, but for patient B this 
treatment was not necessarily overwhelmingly effective 
to control all signs and symptoms of PR such as the car-
diovascular dysfunction which persisted. In the past, cor-
ticosteroids have been in use to manage a variety of forms 
of extrapulmonary TB [8, 9]. Persisting hypotension sug-
gested cardiac (or pericardial) involvement [10]; or over-
whelming TB with sepsis [11, 12]. Although Mtb itself is 
effectively killed by appropriate antimicrobial therapy, an 
exaggerated immune response elicited by the release of 
virulence factors from the cell wall—possibly mediated 
via IL-1 and TNF pathways—may be explanatory for the 
development of PR [11–13]. This mechanism is also able 
to clarify the therapeutic effect exhibited by TNF-a inhibi-
tion, in patients who do not respond to corticosteroids [14, 
15]. Currently, much of the evidence available evaluating 
Fig. 2   a–c Chest X-ray comparison of patient B on day 1(left), day 
26 (middle) and day 64 (right). This sequence of radiographs shows 
an increase of infiltrative consolidation and pleural thickening in the 
LUL, corresponding to the manifestation of PR symptoms and a sub-
sequent reversal of these changes (c) following corticosteroid therapy 
initiation
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the efficacy of corticosteroids in treating PR assesses this 
within the context of TB IRIS (immune reconstitution 
inflammatory syndrome). In this group, the preventative 
value of early administration of prednisone in the devel-
opment of PR has recently been demonstrated [16]. This 
intervention is yet to be applied to those that do not belong 
to this risk group of patients with IRIS following antiret-
roviral therapy.
For patients such as those we have described, formal 
trials are required to shed light on the possible benefits and 
harms caused by steroids and anti-TNF immunosuppres-
sive therapies as well as other alternative approaches. The 
benefits of all of these interventions have been suggested 
in case reports without evidence based on comparative 
studies or randomized trials [17]. Meanwhile, mechanis-
tic immunological studies could help clarify the underly-
ing pathways involved. Currently, we study the incidence 
of PR in TB, and explore anti-inflammatory intervention 
with a macrolide aiming to dampen excessive immune 
activation and structural damage during TB therapy 
[NTC03160638]. In summary, we describe excessive 
inflammatory response following initiation of effective 
antimicrobial therapy for TB. We argue that improved 
understanding and formal studies are needed to provide 
evidence for the treatment of PR.
Fig. 3  a Timeline of patient A. b Timeline of patient B
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